# Gastrointestinal Cancer Program

> **NIH NIH P30** · MAYO CLINIC ROCHESTER · 2021 · $99,431

## Abstract

GASTROINTESTINAL CANCER PROGRAM PROJECT SUMMARY
The Gastrointestinal Cancer (GI) Program of the Mayo Clinic Cancer Center (MCCC) continues to make
significant contributions in the areas of basic, translational, and clinical research by using a multidisciplinary
and interactive team approach. The primary objective of the GI Program is to use novel observations,
mechanistic insights and research outcomes to benefit patients with GI cancers or at risk for GI malignancies,
including those from our catchment area. This work is accomplished through robust intra- and
interprogrammatic interactions focused on 4 Aims: 1) application of early detection approaches, 2)
identification and evaluation of predictive or prognostic biomarkers, 3) role of the tumor microenvironment and
microbiome in cancer development and progression, and 4) individualized therapeutic strategies. Aim 3 is a
new and evolving effort that builds upon an existing base of NCI-funded investigators in these fields of
research, and interacts with the Microbiome Program within the Mayo Clinic Center for Individualized Medicine
to expand the existing germ-free mouse facility and a metabolomics core lab. The GI Program consists of 54
members from 17 departments. Our GI Program developed a SPORE grant in Pancreatic Cancer where major
contributions and interactions continue. The GI Program also developed a Hepatobiliary (HB) SPORE proposal
that received a highly competitive score with a funding decision expected in mid-2018. As a result of this score,
the MCCC was awarded a CCSG supplement of $750K from the NCI with an aim to maintain the infrastructure
for liver cancer research. Our NIH-funded research platform and portfolio of innovative clinical trials is
expanding and benefits from interactions across the 3 MCCC sites and with other multi-institutional networks;
these interactions are enhancing accrual. The GI research program is supported by total direct funding of
$10.2M ($5.1M peer-reviewed, with 69% from NCI). Since 2013, Program members have contributed more
than 871 publications to the literature, of which 28% represent intraprogrammatic and 31% reflect
interprogrammatic collaborations; 21% are in journals with an impact factor ≥10. These publications reflect
numerous scientific accomplishments and discoveries, several of which have been practice changing. Formal
mentoring of junior faculty continues with an increased effort to provide pilot grant funding to our investigators.

## Key facts

- **NIH application ID:** 10113610
- **Project number:** 5P30CA015083-47
- **Recipient organization:** MAYO CLINIC ROCHESTER
- **Principal Investigator:** Tanios Bekaii-Saab
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $99,431
- **Award type:** 5
- **Project period:** 1997-04-25 → 2024-02-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10113610

## Citation

> US National Institutes of Health, RePORTER application 10113610, Gastrointestinal Cancer Program (5P30CA015083-47). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10113610. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*